Intersect ENT (XENT)

Intersect ENT Stock Analysis & Ratings

XENT Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$15.92 - $28.25
Previous Close$28.24
Average Volume (3M)348.69K
Market Cap$954.90M
P/E Ratio-5.6
Next EarningsAug 02, 2022
EPS ForecastN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price TargetN/A
Smart Score7
EPS (TTM)-5.02



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Intersect ENT’s price range in the past 12 months?
Intersect ENT lowest stock price was $15.92 and its highest was $28.25 in the past 12 months.
    What is Intersect ENT’s market cap?
    Intersect ENT’s market cap is $954.90M.
      What is Intersect ENT’s price target?
      Currently, no data Available
      What do analysts say about Intersect ENT?
      Not enough analysts have published a price target to provide an average price target.
      When is Intersect ENT’s upcoming earnings report date?
      Intersect ENT’s upcoming earnings report date is Aug 02, 2022 which is in 76 days.
        How were Intersect ENT’s earnings last quarter?
        Intersect ENT released its earnings results on May 03, 2022. The company reported -$0.854 earnings per share for the quarter, missing the consensus estimate of -$0.318 by -$0.536.
          Is Intersect ENT overvalued?
          According to Wall Street analysts Intersect ENT’s price is currently Overvalued.
            Does Intersect ENT pay dividends?
            Intersect ENT does not currently pay dividends.
            What is Intersect ENT’s EPS estimate?
            Intersect ENT’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Intersect ENT have?
            Intersect ENT has 33,810,000 shares outstanding.
              What happened to Intersect ENT’s price movement after its last earnings report?
              Intersect ENT reported an EPS of -$0.854 in its last earnings report, missing expectations of -$0.318. Following the earnings report the stock price went up 0.398%.
                Which hedge fund is a major shareholder of Intersect ENT?
                Among the largest hedge funds holding Intersect ENT’s share is Carlson Capital LP. It holds Intersect ENT’s shares valued at 4M.


                  Intersect ENT Stock Analysis

                  Smart Score
                  Price Target
                  No data currently available
                  The Intersect ENT stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Intersect ENT

                  Intersect ENT, Inc. is a commercial drug delivery company, which engages in the treatment of ear, nose, and throat conditions. Its products include PROPEL and SINUVA. The PROPEL used to maintain the opening and locally deliver steroid after sinus surgery. The SINUVA is used to treat adult patients with ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps. The company was founded by Donald J. Eaton in October 2003 and is headquartered in Menlo Park, CA.

                  Similar Stocks
                  Price & Change
                  Johnson & Johnson
                  Smith & Nephew Snats

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis